New research into importance of skin surveillance to save lives from melanoma
4 November 2021
New research has provided evidence that routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma – the most deadly form of skin cancer.
Australia has the highest melanoma rates in the world, with one person dying every 6 hours from the disease. Melanoma is also the most common cancer in 20 to 39-year-olds.
The first sign of melanoma is often a new or changing spot or mole on the skin, and the ABCDE guidelines are a helpful tool to identify a melanoma. However, melanoma can vary greatly in its appearance and many subtle clues can only be detected by a trained healthcare professional using a magnifying tool, known as a dermatoscope, to check the skin.
The research, published today in the prestigious journal JAMA Dermatology, found that in a group of 2,452 patients diagnosed with melanoma, slower-growing melanomas were more likely to be detected at a routine skin check and be thinner, whereas faster-growing melanomas were more likely to be patient-detected and thicker. It was estimated that patients whose melanoma was detected by their doctor during a routine skin check were 32% less likely to die from melanoma compared to patients who identified their own melanoma.
The study also found that melanomas easily detected using the ABCDE rule were more likely to be detected by the patients (70%), whereas atypical ones were more often detected by a doctor during a routine skin check.
“This evidence highlights the importance of not only knowing your own skin and seeking advice from your doctor if you notice any changes but also the critical role of trained healthcare professionals for detecting melanomas early, before they have had a chance to spread,” said study author Prof Richard Scolyer AO, pathologist and Co-Medical Director of Melanoma Institute Australia.
Current Australian guidelines recommend that individuals at very high risk of melanoma receive full skin examinations every 6 months. However, melanoma screening programs for the general population are not currently undertaken in Australia because of inadequate evidence that melanoma screening ultimately saves lives, uncertainty about overdiagnosis and unnecessary biopsy, and limited evidence that it is cost effective.
In the last decade there has been renewed interest in melanoma screening, driven by the changing landscape of melanoma care.
“We found that melanoma detection during a routine skin check was associated with lower risk of dying from any cause, but it was not statistically significant for melanoma-specific mortality,” said cancer epidemiologist and lead author Prof Anne Cust, from Melanoma Institute Australia, The Daffodil Centre and The University of Sydney. “Based on our early findings, the cost-effectiveness of a population melanoma screening program should be re-assessed, and a large randomised controlled trial is needed to provide definitive evidence.”
Melanoma Institute Australia has recently launched its ‘Game On Mole’ awareness campaign which uses slogan t-shirts to start conversations about melanoma early detection, and urges Australians to take photos of their skin and monitor for any changes.
To join the campaign and buy the ‘Game On Mole’ t-shirt, go to www.gameonmole.com.au.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.
They are a formidable team - in work and in play
This week, Melanoma Institute Australia hosted the first of six
Federal government urged
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
“I’m the age Emma was when she passed away. It almost feels
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.